0001434868 false 0001434868 2020-01-30 2020-01-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): January 31, 2020

 

Esperion Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware   001-35986   26-1870780
(State or other jurisdiction of
incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification No.)

 

 

3891 Ranchero Drive, Suite 150
Ann Arbor, MI
 

 

48108

(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (734) 887-3903

 

Not Applicable

Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, par value $0.001 per share   ESPR   NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company   ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ¨

 

 

 

 

 

Item 8.01Other Events

 

On January 31, 2020, Esperion Therapeutics, Inc. (the “Company”) issued a press release announcing that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the Marketing Authorisation Application for the bempedoic acid tablet for the treatment of hypercholesterolemia and mixed dyslipidemia. A copy of the Press Release is furnished herewith as Exhibit 99.1.

 

On January 31, 2020, the Company issued a press release announcing that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the Marketing Authorisation Application for the bempedoic acid / ezetimibe fixed dose combination tablet for the treatment of hypercholesterolemia and mixed dyslipidemia. A copy of the Press Release is furnished herewith as Exhibit 99.2.

 

Item9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
99.1   Press Release dated January 31, 2020.
99.2   Press Release dated January 31, 2020.
     
104   The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 31, 2020 Esperion Therapeutics, Inc.
   
  By: /s/ Tim M. Mayleben
    Tim M. Mayleben
    President and Chief Executive Officer

 

3